IQVIA (IQV) 10-Q 29 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 22, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	Q
Entity Registrant Name	Quintiles Transnational Holdings Inc.
Entity Central Index Key	1478242
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		125,022,096

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Service revenues	$1,029,974	$1,005,288
Reimbursed expenses	317,619	302,558
Total revenues	1,347,593	1,307,846
Costs of revenue, service costs	661,827	643,722
Costs of revenue, reimbursed expenses	317,619	302,558
Selling, general and administrative	219,606	219,242
Restructuring costs	5,324	1,008
Income from operations	143,217	141,316
Interest income	-870	-1,255
Interest expense	25,340	24,703
Other (income) expense, net	-2,861	-4,844
Income before income taxes and equity in earnings of unconsolidated affiliates	121,608	122,712
Income tax expense	36,088	37,389
Income before equity in earnings of unconsolidated affiliates	85,520	85,323
Equity in earnings of unconsolidated affiliates	911	4,891
Net income	86,431	90,214
Net income attributable to noncontrolling interests	-33	-31
Net income attributable to Quintiles Transnational Holdings Inc.	$86,398	$90,183
Earnings per share attributable to common shareholders:
Basic	$0.69	$0.69
Diluted	$0.68	$0.68
Weighted average common shares outstanding:
Basic	124,504	129,898
Diluted	127,454	133,040

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement Of Income And Comprehensive Income [Abstract]
Net income	$86,431	$90,214
Unrealized (losses) gains on marketable securities, net of income taxes of ($104) and $1,208	-165	1,930
Unrealized (losses) gains on derivative instruments, net of income taxes of ($1,040) and ($125)	-3,664	322
Foreign currency translation, net of income taxes of ($2,811) and $0	-30,012	303
Reclassification adjustments:
Gains on marketable securities included in net income, net of income taxes of $0 and ($1,927)		-3,077
Losses on derivative instruments included in net income, net of income taxes of $1,656 and $794	3,836	375
Amortization of prior service costs and losses included in net income, net of income taxes of $83 and $72	140	120
Comprehensive income	56,566	90,187
Comprehensive income attributable to noncontrolling interests	-30	-21
Comprehensive income attributable to Quintiles Transnational Holdings Inc.	$56,536	$90,166

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement Of Income And Comprehensive Income [Abstract]
Unrealized (losses) gains on marketable securities, income taxes	($104)	$1,208
Unrealized (losses) gains on derivative instruments, income taxes	-1,040	-125
Foreign currency translation, income taxes	-2,811	0
Gains on marketable securities included in net income, income taxes	0	-1,927
Losses on derivative instruments included in net income, income taxes	1,656	794
Amortization of prior service costs and losses included in net income, income taxes	$83	$72

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$779,068	$867,358
Restricted cash	2,741	2,882
Trade accounts receivable and unbilled services, net	1,006,425	975,255
Prepaid expenses	59,834	44,628
Deferred income taxes	117,933	118,515
Income taxes receivable	44,156	45,357
Other current assets and receivables	88,666	92,088
Total current assets	2,098,823	2,146,083
Property and equipment, net	179,490	190,297
Investments in debt, equity and other securities	34,226	34,503
Investments in and advances to unconsolidated affiliates	34,935	31,508
Goodwill	462,991	464,434
Other identifiable intangibles, net	270,535	280,243
Deferred income taxes	35,635	35,972
Deposits and other assets	120,016	122,792
Total assets	3,236,651	3,305,832
Current liabilities:
Accounts payable and accrued expenses	722,871	842,387
Unearned income	527,684	543,305
Income taxes payable	36,866	55,694
Current portion of long-term debt and obligations held under capital leases	5,940	826
Other current liabilities	27,336	29,688
Total current liabilities	1,320,697	1,471,900
Long-term debt and obligations held under capital leases, less current portion	2,288,229	2,292,491
Deferred income taxes	58,947	61,797
Other liabilities	181,085	183,656
Total liabilities	3,848,958	4,009,844
Commitments and contingencies
Shareholders’ deficit:
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 124,950 and 124,129 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	178,966	143,828
Accumulated deficit	-702,400	-788,798
Accumulated other comprehensive loss	-88,953	-59,091
Deficit attributable to Quintiles Transnational Holdings Inc.’s shareholders	-612,387	-704,061
Noncontrolling interests	80	49
Total shareholders’ deficit	-612,307	-704,012
Total liabilities and shareholders’ deficit	$3,236,651	$3,305,832

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Statement Of Financial Position [Abstract]
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$0.01	$0.01
Common stock, shares issued	124,950,000	124,129,000
Common stock, shares outstanding	124,950,000	124,129,000

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating activities :
Net income	$86,431	$90,214
Adjustments to reconcile net income to cash used in operating activities:
Depreciation and amortization	30,329	29,088
Amortization of debt issuance costs and discount	1,677	1,595
Share-based compensation	9,574	7,221
Earnings from unconsolidated affiliates	-911	-4,891
Loss (gain) on investments, net	5	-5,268
Benefit from deferred income taxes	-884	-1,587
Excess income tax benefits from share-based award activities	-9,077	-5,840
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	-63,460	-51,018
Change in other operating assets and liabilities	-118,016	-87,951
Net cash used in operating activities	-64,332	-28,437
Investing activities:
Acquisition of property, equipment and software	-16,432	-17,706
Proceeds from sale of equity securities		5,861
Investments in and advances to unconsolidated affiliates, net of payments received	-2,542	-1,224
Other	666	-910
Net cash used in investing activities	-18,308	-13,979
Financing activities:
Payment of debt issuance costs	-19
Repayment of debt and principal payments on capital lease obligations	-1,210	-334
Stock issued under employee stock purchase and option plans	18,494	5,916
Payroll taxes remitted on repurchase of stock options		-8,415
Excess income tax benefits from share-based award activities	9,077	5,840
Net cash provided by financing activities	26,342	3,007
Effect of foreign currency exchange rate changes on cash	-31,992	2,647
Decrease in cash and cash equivalents	-88,290	-36,762
Cash and cash equivalents at beginning of period	867,358	778,143
Cash and cash equivalents at end of period	$779,068	$741,381

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies
	Unaudited Interim Financial Information
	The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
	Reclassifications
	Certain immaterial prior period amounts have been reclassified to conform to current period presentation. These changes had no effect on previously reported total revenues, net income, comprehensive income, shareholders’ deficit or cash flows.
	Recently Issued Accounting Standards
	In April 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance that will require debt issuance costs to be presented as a direct deduction from the carrying amount of the related debt liability on the balance sheet, instead of being presented as an asset. The Company will adopt the new accounting guidance during the second quarter of 2015. The adoption of the new accounting guidance is not expected to have a material effect on the Company’s financial statements.
	In February 2015, the FASB issued new accounting guidance which changes the analysis in determining whether an entity is considered a variable interest entity (“VIE”) and the identification of the primary beneficiary of the VIE to determine whether the VIE should be included in an entity’s consolidated financial statements. The Company will adopt the new accounting guidance on January 1, 2016, as required. The Company is currently evaluating the impact of this update on its consolidated financial statements.
	In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition and changes in assets and liabilities that result from contracts with customers. The Company will adopt the new standard on January 1, 2017, as required. Early adoption is not permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.
	Research and Development Costs
	In January 2010, the Company entered into a collaboration agreement with a related party, HUYA Bioscience International, LLC (“HUYA”), to fund up to $2.3 million of its research and development activity for a specific compound. Under the agreement, the Company had the potential to receive additional consideration which contractually would not exceed $16.5 million excluding interest if certain events had occurred. In February 2015, the Company and HUYA agreed to terminate the collaboration agreement, In connection with the termination, HUYA paid the Company $5.0 million to satisfy all of HUYA’s various payment obligations under the collaboration agreement.

Employee_Stock_Compensation

Employee Stock Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Employee Stock Compensation	2. Employee Stock Compensation
	The Company granted the following share-based awards:
		Three Months Ended March 31,
		2015		2014
	Stock options		923,700		1,024,500
	Stock appreciation rights		176,200		176,800
	Restricted stock units		226,821	—
	Performance units		51,977	—
	The Company had the following share-based awards outstanding:
		March 31,		December 31,
		2015		2014
	Stock options		9,096,191		9,124,954
	Stock appreciation rights		580,901		418,801
	Restricted stock units		320,488		93,667
	Performance units		51,977	—
	The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows:
		Three Months Ended March 31,
		2015		2014
	Expected volatility	30 - 41%		32 – 43%
	Weighted average expected volatility		35%		38%
	Expected dividends		0.00%		0.00%
	Expected term (in years)	3.7 - 6.7		3.7 – 6.7
	Risk-free interest rate	1.06 - 1.88%		0.99 – 2.21%
	In March 2015, the Company awarded performance units that contain both service and performance based vesting criteria. Vesting occurs if the recipient remains employed and depends on the degree to which the Company achieves certain cumulative adjusted diluted earnings per share goals during a three-year performance period (as defined in the award agreements). The fair value of these awards is equal to the closing price of the Company’s common stock on the grant date.
	In November 2013, the Company’s Board of Directors (the “Board”) approved an Employee Stock Purchase Plan (“ESPP”) which was approved by the Company’s shareholders in May 2014. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary to be applied toward the purchase of full shares of the Company’s common stock on the last day of the offering period. Offering periods under the ESPP are six months in duration. The first two offering periods for the ESPP began March 1, 2014 and September 1, 2014, respectively. In November 2014, the ESPP was amended to change the start of the offering periods to begin on April 1 and October 1 of each year, beginning April 1, 2015. Participating employees purchase shares on the last day of each offering period at a discount of 15% of the closing price of the common stock on such date as reported on the New York Stock Exchange. During the three months ended March 31, 2015, the Company issued 38,449 shares of common stock for purchases under the ESPP.
	The Company recognized share-based compensation expense of $9.6 million and $7.2 million during the three months ended March 31, 2015 and 2014, respectively.

Concentration_of_Credit_Risk

Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2015
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	3. Concentration of Credit Risk
	No customer accounted for 10% or more of consolidated service revenues for the three months ended March 31, 2015 or 2014.

Accounts_Receivable_and_Unbill

Accounts Receivable and Unbilled Services	3 Months Ended
	Mar. 31, 2015
Receivables [Abstract]
Accounts Receivable and Unbilled Services	4. Accounts Receivable and Unbilled Services
	Accounts receivable and unbilled services consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Trade:
	Billed	$	451,702		$	444,941
	Unbilled services		556,287			532,312
			1,007,989			977,253
	Allowance for doubtful accounts		(1,564	)		(1,998	)
		$	1,006,425		$	975,255

Business_Combination

Business Combination	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination	5. Business Combination
	On March 30, 2015, the Company signed a definitive agreement to combine its global central laboratories business with the central laboratory testing business of Quest Diagnostics Incorporated. The Company believes the combined capabilities will provide customers with globally scaled end-to-end central laboratory services. The transaction, which will be accounted for as a business combination, is expected to close in 2015 and is subject to regulatory approval and standard and customary closing conditions.

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	6. Goodwill
	The following is a summary of goodwill by segment for the three months ended March 31, 2015 (in thousands):
					Integrated
		Product			Healthcare
		Development			Services			Consolidated
	Balance as of December 31, 2014	$	346,608		$	117,826		$	464,434
	Impact of foreign currency fluctuations		(1,340	)		(103	)		(1,443	)
	Balance as of March 31, 2015	$	345,268		$	117,723		$	462,991

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivatives	7. Derivatives
	As of March 31, 2015, the Company held the following derivative positions: (i) forward exchange contracts to protect against foreign exchange movements for certain forecasted foreign currency cash flows related to service contracts and (ii) interest rate swaps to hedge the exposure to variability in interest payments on variable interest rate debt. The Company does not use derivative financial instruments for speculative or trading purposes.
	As of March 31, 2015, the Company had 17 open foreign exchange forward contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2015 with notional amounts totaling $95.8 million. As these contracts were executed to hedge the risk of the potential volatility in the cash flows resulting from fluctuations in currency exchange rates during the last nine months of 2015, these transactions are accounted for as cash flow hedges. As such, the effective portion of the gain or loss on the contracts is recorded as unrealized gains (losses) on derivatives included in the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit. These hedges are highly effective. Upon expiration of the hedge instruments in 2015, the Company will reclassify the unrealized holding gains and losses on the derivative instruments included in AOCI into earnings.
	On June 9, 2011, the Company entered into six interest rate swaps effective September 28, 2012 and expiring between September 30, 2013 and March 31, 2016 in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. The critical terms of the interest rate swaps were substantially the same as those of the Company’s senior secured credit facilities, including quarterly interest settlements. These interest rate swaps are being accounted for as cash flow hedges as these transactions were executed to hedge the Company’s interest payments, and these hedges are deemed to be highly effective. As such, changes in the fair value of these derivative instruments are recorded as unrealized gains (losses) on derivatives included in the AOCI component of shareholders’ deficit. The fair value of these interest rate swaps represents the present value of the anticipated net payments the Company will make to the counterparty, which, when they occur, are reflected as interest expense on the condensed consolidated statements of income. These payments, together with the variable rate of interest incurred on the underlying debt, result in a fixed rate of interest of 2.57% plus the applicable margin on the affected borrowings ($910.0 million or 44.8% of the Company’s variable rate debt at March 31, 2015). The Company expects that $12.2 million of unrealized losses will be reclassified out of AOCI and will form the interest rate swap component of the 2.57% fixed rate of interest incurred over the next 12 months as the underlying net payments are settled.
	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands):
		Balance Sheet Classification		March 31,				December 31,
				2015				2014
	Foreign exchange forward contracts	Other current liabilities		$	6,324			$	4,635
	Interest rate swaps	Other current liabilities		$	11,947			$	14,424
	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands):
		Three Months Ended March 31,
		2015				2014
	Foreign exchange forward contracts	$	(1,689	)		$	(809	)
	Interest rate swaps		2,477				2,175
	Total	$	788			$	1,366

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	8. Fair Value Measurements
	The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
	·	Level 1 — Quoted prices in active markets for identical assets or liabilities.
	·	Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	·	Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
	Recurring Fair Value Measurements
	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of March 31, 2015 (in thousands):
			Level 1		Level 2			Level 3		Total
	Assets:
	Marketable equity securities		$	563	$	—		$	—	$	563
	Total		$	563	$	—		$	—	$	563
	Liabilities:
	Foreign exchange forward contracts		$	—	$	6,324		$	—	$	6,324
	Interest rate swaps		—			11,947		—			11,947
	Contingent consideration		—		—				2,739		2,739
	Total		$	—	$	18,271		$	2,739	$	21,010
	Below is a summary of the valuation techniques used in determining fair value:
	Marketable equity securities — The Company values marketable equity securities utilizing quoted market prices.
	Foreign exchange forward contracts — The Company values foreign exchange forward contracts using quoted market prices for identical instruments in less active markets or using other observable inputs.
	Interest rate swaps — The Company values interest rate swaps using market inputs with mid-market pricing as a practical expedient for bid-ask spread.
	Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating forecasts and the probability of achieving the specific targets.
	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the three months ended March 31 (in thousands):
			Contingent Consideration –
			Accounts Payable and Accrued
			Expenses and Other Liabilities
			2015		2014
	Balance as of January 1		$	1,452	$	13,014
	Revaluations included in earnings			1,287		(82	)
	Balance as of March 31		$	2,739	$	12,932
	The revaluations for the contingent consideration are recognized in other (income) expense, net on the accompanying condensed consolidated statements of income.
	Non-recurring Fair Value Measurements
	Certain assets are carried on the accompanying condensed consolidated balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include cost and equity method investments and loans that are written down to fair value for declines which are deemed to be other-than-temporary, and goodwill and identifiable intangible assets which are tested for impairment annually and when a triggering event occurs.
	As of March 31, 2015, assets carried on the balance sheet and not remeasured to fair value on a recurring basis totaling approximately $802.1 million were identified as Level 3. These assets are comprised of cost and equity method investments of $68.6 million, goodwill of $463.0 million and other identifiable intangibles, net of $270.5 million.
	The Company has unfunded cash commitments totaling approximately $42.5 million related to its cost and equity method investments as of March 31, 2015.
	Other
	The estimated fair value of the Company’s long-term debt approximates its carrying value as of March 31, 2015 and December 31, 2014. The estimated fair value of the long-term debt is primarily based on rates in which the debt is traded among banks.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2015
Restructuring And Related Activities [Abstract]
Restructuring	9. Restructuring
	In February 2015, the Board approved a restructuring plan for approximately $30.0 million to align the Company’s resources and reduce overcapacity. These actions are expected to occur throughout 2015 and 2016, and are expected to consist of severance, facility closure and other exit-related costs. Since February 2015, the Company has recognized approximately $4.3 million, $468,000 and $259,000 of restructuring costs related to this plan for activities in the Product Development segment, Integrated Healthcare Services segment and corporate activities, respectively. All of the restructuring costs are related to severance costs. Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management.
	The following amounts were recorded for the February 2015 restructuring plan and the restructuring plans initiated in prior years (in thousands):
		Severance and			Exit Costs			Total
		Related Costs
	Balance at December 31, 2014	$	5,478		$	605		$	6,083
	Expense, net of reversals		4,969			355			5,324
	Payments		(3,935	)		(351	)		(4,286	)
	Foreign currency translation		(211	)		—			(211	)
	Balance at March 31, 2015	$	6,301		$	609		$	6,910
	The Company expects the majority of the restructuring accruals at March 31, 2015 will be paid in 2015.

Employee_Benefit_Plans

Employee Benefit Plans	3 Months Ended
	Mar. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	10. Employee Benefit Plans
	Defined Benefit Plans
	The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands):
		Three months ended March 31,
		2015			2014
	Service cost	$	3,614		$	3,287
	Interest cost		867			987
	Expected return on plan assets		(853	)		(928	)
	Amortization of prior service costs		—			20
	Amortization of actuarial losses		223			172
		$	3,851		$	3,538
	Other
	As of March 31, 2015 and December 31, 2014, the Company had a severance accrual included in accounts payable and accrued expenses on the accompanying condensed consolidated balance sheets of $5.1 million and $6.3 million, respectively. The Company recognizes obligations associated with severance related to contractual termination benefits at fair value on the date that it is probable that the affected employees will be entitled to the benefit and the amount can reasonably be estimated. The severance accrual is related to cost reduction programs that will result in severance for approximately 270 positions, which are expected to lower operating costs and improve profitability. During the first quarter of 2015, the Company recognized approximately $443,000 of net reversals related to these cost reduction programs, primarily as a result of affected individuals transferring into other positions within the Company. Of the $443,000 decrease from net reversals recognized for these cost reduction programs, approximately $347,000 and $96,000 were related to activities in the Product Development segment and Integrated Healthcare Services segment, respectively. The Company expects the majority of the severance accrual at March 31, 2015 will be paid in 2015.
	The following amounts were recorded for the severance associated with cost reduction programs (in thousands):
	Balance at December 31, 2014	$	6,274
	Expense, net of reversals		(443	)
	Payments		(666	)
	Foreign currency translation		(28	)
	Balance at March 31, 2015	$	5,137

Comprehensive_Income

Comprehensive Income	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Comprehensive Income	11. Comprehensive Income
	Below is a summary of the components of AOCI (in thousands):
		Foreign				Marketable				Derivative			Defined			Income			Total
		Currency				Securities				Instruments			Benefit			Taxes
		Translation											Plans
	Balance at December 31, 2014	$	(55,740	)		$	(272	)		$	(19,059	)	$	(14,519	)	$	30,499		$	(59,091	)
	Other comprehensive (loss) income before reclassifications		(32,820	)			(269	)			(4,704	)		—			3,955			(33,838	)
	Reclassification adjustments		—				—				5,492			223			(1,739	)		3,976
	Balance at March 31, 2015	$	(88,560	)		$	(541	)		$	(18,271	)	$	(14,296	)	$	32,715		$	(88,953	)
	Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands):
	Reclassification Adjustments	Affected Financial Statement		Three months ended March 31,
		Line Item
				2015				2014
	Marketable securities:
	Marketable securities	Other (income) expense, net		$	—			$	(5,004	)
	Total before income taxes				—				(5,004	)
	Income tax expense				—				(1,927	)
	Total net of income taxes			$	—			$	(3,077	)
	Derivative instruments:
	Interest rate swaps	Interest expense		$	3,013			$	3,080
	Foreign exchange forward contracts	Service revenues			2,479				(1,911	)
	Total before income taxes				5,492				1,169
	Income tax benefit				1,656				794
	Total net of income taxes			$	3,836			$	375
	Defined benefit plans:
	Amortization of prior service costs	See Note 10		$	—			$	20
	Amortization of actuarial losses	See Note 10			223				172
	Total before income taxes				223				192
	Income tax benefit				83				72
	Total net of income taxes			$	140			$	120

Segments

Segments	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segments	12. Segments
	The following table presents the Company’s operations by reportable segment. The Company is managed through two reportable segments, Product Development and Integrated Healthcare Services. Product Development, which primarily serves biopharmaceutical customers engaged in research and development, provides clinical research and clinical trial services. Integrated Healthcare Services provides commercialization services to biopharmaceutical customers and research, analytics, real-world and late phase research, and other services to both biopharmaceutical customers and the broader healthcare market.
	Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of share-based compensation and expenses for corporate overhead functions such as finance, human resources, information technology, facilities and legal. The Company does not allocate restructuring or impairment charges to its segments. Information presented below is in thousands:
		Three Months Ended March 31,
		2015			2014
	Service revenues
	Product Development	$	749,529		$	770,828
	Integrated Healthcare Services		280,445			234,460
	Total service revenues		1,029,974			1,005,288
	Costs of revenue, service costs
	Product Development		437,422			450,483
	Integrated Healthcare Services		224,405			193,239
	Total costs of revenue, service costs		661,827			643,722
	Selling, general and administrative
	Product Development		155,108			159,685
	Integrated Healthcare Services		37,922			32,276
	General corporate and unallocated		26,576			27,281
	Total selling, general and administrative		219,606			219,242
	Income from operations
	Product Development		156,999			160,660
	Integrated Healthcare Services		18,118			8,945
	General corporate and unallocated		(26,576	)		(27,281	)
	Restructuring costs		(5,324	)		(1,008	)
	Total income from operations	$	143,217		$	141,316
		Three Months Ended March 31,
		2015			2014
	Depreciation and amortization expense
	Product Development	$	23,876		$	22,970
	Integrated Healthcare Services		5,208			4,891
	General corporate and unallocated		1,245			1,227
	Total depreciation and amortization expense	$	30,329		$	29,088

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share	13. Earnings Per Share
	The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands):
		Three Months Ended March 31,
		2015		2014
	Weighted average shares subject to anti-dilutive share-based awards		1,043		766
	Share-based awards will have a dilutive effect under the treasury method only when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	14. Subsequent Event
	In April 2015, the Company's Board of Directors increased its share repurchase authorization under the previously approved share repurchase program by $300 million. The total authorization available for share repurchases is approximately $360 million. The share repurchase program does not obligate the Company to acquire any particular amount of common stock, and may be modified, extended, suspended or discontinued at any time. The program does not have an end date.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information
	The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
Reclassifications	Reclassifications
	Certain immaterial prior period amounts have been reclassified to conform to current period presentation. These changes had no effect on previously reported total revenues, net income, comprehensive income, shareholders’ deficit or cash flows.
Recently Issued Accounting Standards	Recently Issued Accounting Standards
	In April 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance that will require debt issuance costs to be presented as a direct deduction from the carrying amount of the related debt liability on the balance sheet, instead of being presented as an asset. The Company will adopt the new accounting guidance during the second quarter of 2015. The adoption of the new accounting guidance is not expected to have a material effect on the Company’s financial statements.
	In February 2015, the FASB issued new accounting guidance which changes the analysis in determining whether an entity is considered a variable interest entity (“VIE”) and the identification of the primary beneficiary of the VIE to determine whether the VIE should be included in an entity’s consolidated financial statements. The Company will adopt the new accounting guidance on January 1, 2016, as required. The Company is currently evaluating the impact of this update on its consolidated financial statements.
	In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition and changes in assets and liabilities that result from contracts with customers. The Company will adopt the new standard on January 1, 2017, as required. Early adoption is not permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.
Research and Development Costs	Research and Development Costs
	In January 2010, the Company entered into a collaboration agreement with a related party, HUYA Bioscience International, LLC (“HUYA”), to fund up to $2.3 million of its research and development activity for a specific compound. Under the agreement, the Company had the potential to receive additional consideration which contractually would not exceed $16.5 million excluding interest if certain events had occurred. In February 2015, the Company and HUYA agreed to terminate the collaboration agreement, In connection with the termination, HUYA paid the Company $5.0 million to satisfy all of HUYA’s various payment obligations under the collaboration agreement.

Employee_Stock_Compensation_Ta

Employee Stock Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-Based Awards Granted and Outstanding	The Company granted the following share-based awards:
		Three Months Ended March 31,
		2015		2014
	Stock options		923,700		1,024,500
	Stock appreciation rights		176,200		176,800
	Restricted stock units		226,821	—
	Performance units		51,977	—
	The Company had the following share-based awards outstanding:
		March 31,		December 31,
		2015		2014
	Stock options		9,096,191		9,124,954
	Stock appreciation rights		580,901		418,801
	Restricted stock units		320,488		93,667
	Performance units		51,977	—
Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued	The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows:
		Three Months Ended March 31,
		2015		2014
	Expected volatility	30 - 41%		32 – 43%
	Weighted average expected volatility		35%		38%
	Expected dividends		0.00%		0.00%
	Expected term (in years)	3.7 - 6.7		3.7 – 6.7
	Risk-free interest rate	1.06 - 1.88%		0.99 – 2.21%

Accounts_Receivable_and_Unbill1

Accounts Receivable and Unbilled Services (Tables)	3 Months Ended
	Mar. 31, 2015
Receivables [Abstract]
Accounts Receivable and Unbilled Services	Accounts receivable and unbilled services consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Trade:
	Billed	$	451,702		$	444,941
	Unbilled services		556,287			532,312
			1,007,989			977,253
	Allowance for doubtful accounts		(1,564	)		(1,998	)
		$	1,006,425		$	975,255

Goodwill_Tables

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Segment	The following is a summary of goodwill by segment for the three months ended March 31, 2015 (in thousands):
					Integrated
		Product			Healthcare
		Development			Services			Consolidated
	Balance as of December 31, 2014	$	346,608		$	117,826		$	464,434
	Impact of foreign currency fluctuations		(1,340	)		(103	)		(1,443	)
	Balance as of March 31, 2015	$	345,268		$	117,723		$	462,991

Derivatives_Tables

Derivatives (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands):
		Balance Sheet Classification		March 31,				December 31,
				2015				2014
	Foreign exchange forward contracts	Other current liabilities		$	6,324			$	4,635
	Interest rate swaps	Other current liabilities		$	11,947			$	14,424
Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss)	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands):
		Three Months Ended March 31,
		2015				2014
	Foreign exchange forward contracts	$	(1,689	)		$	(809	)
	Interest rate swaps		2,477				2,175
	Total	$	788			$	1,366

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of March 31, 2015 (in thousands):
		Level 1		Level 2			Level 3		Total
	Assets:
	Marketable equity securities	$	563	$	—		$	—	$	563
	Total	$	563	$	—		$	—	$	563
	Liabilities:
	Foreign exchange forward contracts	$	—	$	6,324		$	—	$	6,324
	Interest rate swaps	—			11,947		—			11,947
	Contingent consideration	—		—				2,739		2,739
	Total	$	—	$	18,271		$	2,739	$	21,010
Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the three months ended March 31 (in thousands):
		Contingent Consideration –
		Accounts Payable and Accrued
		Expenses and Other Liabilities
		2015		2014
	Balance as of January 1	$	1,452	$	13,014
	Revaluations included in earnings		1,287		(82	)
	Balance as of March 31	$	2,739	$	12,932

Restructuring_Tables

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2015
Restructuring And Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the February 2015 restructuring plan and the restructuring plans initiated in prior years (in thousands):
		Severance and			Exit Costs			Total
		Related Costs
	Balance at December 31, 2014	$	5,478		$	605		$	6,083
	Expense, net of reversals		4,969			355			5,324
	Payments		(3,935	)		(351	)		(4,286	)
	Foreign currency translation		(211	)		—			(211	)
	Balance at March 31, 2015	$	6,301		$	609		$	6,910

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Summary of Components of Pension Expenses Related to Defined Benefit Plans	The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands):
		Three months ended March 31,
		2015			2014
	Service cost	$	3,614		$	3,287
	Interest cost		867			987
	Expected return on plan assets		(853	)		(928	)
	Amortization of prior service costs		—			20
	Amortization of actuarial losses		223			172
		$	3,851		$	3,538
Summary of Severance Associated with Cost Reduction Programs	The following amounts were recorded for the severance associated with cost reduction programs (in thousands):
	Balance at December 31, 2014	$	6,274
	Expense, net of reversals		(443	)
	Payments		(666	)
	Foreign currency translation		(28	)
	Balance at March 31, 2015	$	5,137

Comprehensive_Income_Tables

Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI (in thousands):
		Foreign				Marketable				Derivative			Defined			Income			Total
		Currency				Securities				Instruments			Benefit			Taxes
		Translation											Plans
	Balance at December 31, 2014	$	(55,740	)		$	(272	)		$	(19,059	)	$	(14,519	)	$	30,499		$	(59,091	)
	Other comprehensive (loss) income before reclassifications		(32,820	)			(269	)			(4,704	)		—			3,955			(33,838	)
	Reclassification adjustments		—				—				5,492			223			(1,739	)		3,976
	Balance at March 31, 2015	$	(88,560	)		$	(541	)		$	(18,271	)	$	(14,296	)	$	32,715		$	(88,953	)
Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands):
	Reclassification Adjustments	Affected Financial Statement		Three months ended March 31,
		Line Item
				2015				2014
	Marketable securities:
	Marketable securities	Other (income) expense, net		$	—			$	(5,004	)
	Total before income taxes				—				(5,004	)
	Income tax expense				—				(1,927	)
	Total net of income taxes			$	—			$	(3,077	)
	Derivative instruments:
	Interest rate swaps	Interest expense		$	3,013			$	3,080
	Foreign exchange forward contracts	Service revenues			2,479				(1,911	)
	Total before income taxes				5,492				1,169
	Income tax benefit				1,656				794
	Total net of income taxes			$	3,836			$	375
	Defined benefit plans:
	Amortization of prior service costs	See Note 10		$	—			$	20
	Amortization of actuarial losses	See Note 10			223				172
	Total before income taxes				223				192
	Income tax benefit				83				72
	Total net of income taxes			$	140			$	120

Segments_Tables

Segments (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Information presented below is in thousands:
		Three Months Ended March 31,
		2015			2014
	Service revenues
	Product Development	$	749,529		$	770,828
	Integrated Healthcare Services		280,445			234,460
	Total service revenues		1,029,974			1,005,288
	Costs of revenue, service costs
	Product Development		437,422			450,483
	Integrated Healthcare Services		224,405			193,239
	Total costs of revenue, service costs		661,827			643,722
	Selling, general and administrative
	Product Development		155,108			159,685
	Integrated Healthcare Services		37,922			32,276
	General corporate and unallocated		26,576			27,281
	Total selling, general and administrative		219,606			219,242
	Income from operations
	Product Development		156,999			160,660
	Integrated Healthcare Services		18,118			8,945
	General corporate and unallocated		(26,576	)		(27,281	)
	Restructuring costs		(5,324	)		(1,008	)
	Total income from operations	$	143,217		$	141,316
Depreciation and Amortization Expense
		Three Months Ended March 31,
		2015			2014
	Depreciation and amortization expense
	Product Development	$	23,876		$	22,970
	Integrated Healthcare Services		5,208			4,891
	General corporate and unallocated		1,245			1,227
	Total depreciation and amortization expense	$	30,329		$	29,088

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Stock Options Excluded from Computation of Diluted Earnings Per Share	The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands):
		Three Months Ended March 31,
		2015		2014
	Weighted average shares subject to anti-dilutive share-based awards		1,043		766

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Mar. 31, 2015
Accounting Policies [Abstract]
Related party fund to research and development activity		$2.30
Additional consideration agreement		16.5
Gain on termination of collaboration agreement	$5

Employee_Stock_Compensation_Sc

Employee Stock Compensation - Schedule of Share-Based Awards Granted and Outstanding (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock options granted	923,700	1,024,500
Stock appreciation rights granted	176,200	176,800
Restricted stock units granted	226,821
Performance units granted	51,977
Stock options outstanding	9,096,191		9,124,954
Stock appreciation rights outstanding	580,901		418,801
Restricted stock units outstanding	320,488		93,667
Performance units outstanding	51,977

Employee_Stock_Compensation_As

Employee Stock Compensation - Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected volatility, Minimum	30.00%	32.00%
Expected volatility, Maximum	41.00%	43.00%
Weighted average expected volatility	35.00%	38.00%
Expected dividends	0.00%	0.00%
Risk-free interest rate, Minimum	1.06%	0.99%
Risk-free interest rate, Maximum	1.88%	2.21%
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	3 years 8 months 12 days	3 years 8 months 12 days
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	6 years 8 months 12 days	6 years 8 months 12 days

Employee_Stock_Compensation_Ad

Employee Stock Compensation - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense	$9,574	$7,221
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase plan payroll deductions percent	10.00%
Discount on closing price of share	15.00%
Common stock shares purchase	38,449

Concentration_of_Credit_Risk_A

Concentration of Credit Risk - Additional Information (Detail) (Customer Concentration Risk [Member], Sales Revenue [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
	Customer	Customer
Customer Concentration Risk [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Number of customers served	0	0
Percentage of service revenue from major customers	10.00%	10.00%

Accounts_Receivable_and_Unbill2

Accounts Receivable and Unbilled Services - Accounts Receivable and Unbilled Services (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Trade:
Billed	$451,702	$444,941
Unbilled services	556,287	532,312
Trade accounts receivable and unbilled services, gross	1,007,989	977,253
Allowance for doubtful accounts	-1,564	-1,998
Trade accounts receivable and unbilled services, net	$1,006,425	$975,255

Goodwill_Summary_of_Goodwill_b

Goodwill - Summary of Goodwill by Segment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Goodwill [Line Items]
Beginning Balance	$464,434
Impact of foreign currency fluctuations	-1,443
Ending Balance	462,991
Product Development [Member]
Goodwill [Line Items]
Beginning Balance	346,608
Impact of foreign currency fluctuations	-1,340
Ending Balance	345,268
Integrated Healthcare Services [Member]
Goodwill [Line Items]
Beginning Balance	117,826
Impact of foreign currency fluctuations	-103
Ending Balance	$117,723

Derivatives_Additional_Informa

Derivatives - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Jun. 09, 2011
		Agreement
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative fixed interest rate	2.57%
Interest rate swaps effectively converted percent	44.80%
Interest rate cash flow hedge loss to be reclassified during next 12 months, net	-12,200,000
Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	30-Sep-13
Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	31-Mar-16
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts	17
Notional amount	95,800,000
Expiration year of hedge instruments	2015
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts		6
Interest rate swaps hedged amount due to future change in interest rate swaps	910,000,000

Derivatives_Summary_of_Fair_Va

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) (Designated as Hedging Instrument [Member], Other Current Liabilities [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Foreign Exchange Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$6,324	$4,635
Interest Rate Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$11,947	$14,424

Derivatives_Effect_of_Cash_Flo

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss) (Detail) (Derivatives Designated As Cash Flow Hedges [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$788	$1,366
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	-1,689	-809
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$2,477	$2,175

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) (Recurring Fair Value Measurements [Member], USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	$563
Fair value of liabilities	21,010
Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	6,324
Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	11,947
Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	2,739
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	563
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	18,271
Level 2 [Member] | Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	6,324
Level 2 [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	11,947
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	2,739
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of liabilities	2,739
Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	563
Marketable Equity Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Fair value of assets	$563

Fair_Value_Measurements_Change

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) (Accounts Payable and Accrued Expenses and Other Liabilities [Member], Contingent Consideration [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Accounts Payable and Accrued Expenses and Other Liabilities [Member] | Contingent Consideration [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance, Contingent Consideration	$1,452	$13,014
Revaluations included in earnings	1,287	-82
Ending Balance, Contingent Consideration	$2,739	$12,932

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other identifiable intangibles, net	$270,535,000	$280,243,000
Non-recurring Fair Value Measurements [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	802,100,000
Cost and equity method investments	68,600,000
Goodwill	463,000,000
Other identifiable intangibles, net	270,500,000
Non-recurring Fair Value Measurements [Member] | Level 3 [Member] | Equity Method Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unfunded cash commitments	$42,500,000

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	3 Months Ended		2 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Feb. 28, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$5,324,000	$1,008,000
2015 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved				30,000,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			4,300,000
2015 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			468,000
2015 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$259,000

Restructuring_Summary_of_Amoun

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	$6,083,000
Restructuring costs	5,324,000	1,008,000
Payments	-4,286,000
Foreign currency translation	-211,000
Restructuring reserves, ending balance	6,910,000
Severance and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	5,478,000
Restructuring costs	4,969,000
Payments	-3,935,000
Foreign currency translation	-211,000
Restructuring reserves, ending balance	6,301,000
Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	605,000
Restructuring costs	355,000
Payments	-351,000
Restructuring reserves, ending balance	$609,000

Employee_Benefit_Plans_Summary

Employee Benefit Plans - Summary of Components of Pension Expenses Related to Defined Benefit Plans (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Service cost	$3,614	$3,287
Interest cost	867	987
Expected return on plan assets	-853	-928
Amortization of prior service costs		20
Amortization of actuarial losses	223	172
Total pension expense related to defined benefit plans	$3,851	$3,538

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expenses payable	$5,137,000	$6,274,000
Severance expense, net of reversals	443,000
Product Development [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	347,000
Integrated Healthcare Services [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	96,000
Cost Reduction Initiative [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expenses payable	$5,100,000		$6,300,000
Number of positions expected to be eliminated	270

Employee_Benefit_Plans_Summary1

Employee Benefit Plans - Summary of Severance Associated with Cost Reduction Programs (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Severance expenses payable, opening balance	$6,274,000
Severance expense, net of reversals	-443,000
Severance payments	-666,000
Severance foreign currency translation	-28,000
Severance expenses payable, ending balance	$5,137,000

Comprehensive_Income_Summary_o

Comprehensive Income - Summary of Components of AOCI (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	($59,091)
Other comprehensive (loss) income before reclassifications	-33,838
Reclassification adjustments	3,976
Ending Balance	-88,953
Foreign Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	-55,740
Other comprehensive (loss) income before reclassifications	-32,820
Ending Balance	-88,560
Marketable Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	-272
Other comprehensive (loss) income before reclassifications	-269
Ending Balance	-541
Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	-19,059
Other comprehensive (loss) income before reclassifications	-4,704
Reclassification adjustments	5,492
Ending Balance	-18,271
Defined Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	-14,519
Reclassification adjustments	223
Ending Balance	-14,296
Income Taxes [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	30,499
Other comprehensive (loss) income before reclassifications	3,955
Reclassification adjustments	-1,739
Ending Balance	$32,715

Comprehensive_Income_Summary_o1

Comprehensive Income - Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Marketable securities, Other (income) expense, net	($2,861)	($4,844)
Income tax expense/benefit	-36,088	-37,389
Foreign exchange forward contracts, Service revenues	-1,347,593	-1,307,846
Amortization of prior service costs		20
Amortization of actuarial losses	223	172
Marketable Securities [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Marketable securities, Other (income) expense, net		-5,004
Total before income taxes		-5,004
Income tax expense/benefit		-1,927
Total net of income taxes		-3,077
Defined Benefit Plans [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	223	192
Income tax expense/benefit	83	72
Total net of income taxes	140	120
Amortization of prior service costs		20
Amortization of actuarial losses	223	172
Derivative [Member] | Derivative Instruments [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	5,492	1,169
Income tax expense/benefit	1,656	794
Total net of income taxes	3,836	375
Interest Rate Swaps [Member] | Derivative Instruments [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest rate swaps, Interest expense	3,013	3,080
Foreign Exchange Forward Contracts [Member] | Derivative Instruments [Member] | Reclassification Adjustments from Accumulated Other Comprehensive (Loss) Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Foreign exchange forward contracts, Service revenues	($2,479)	$1,911

Segments_Additional_Informatio

Segments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segments_Operations_by_Reporta

Segments - Operations by Reportable Segments (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Service revenues	$1,029,974,000	$1,005,288,000
Costs of revenue, service costs	661,827,000	643,722,000
Selling, general and administrative	219,606,000	219,242,000
Income from operations	143,217,000	141,316,000
Restructuring costs	-5,324,000	-1,008,000
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Service revenues	749,529,000	770,828,000
Costs of revenue, service costs	437,422,000	450,483,000
Selling, general and administrative	155,108,000	159,685,000
Income from operations	156,999,000	160,660,000
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Service revenues	280,445,000	234,460,000
Costs of revenue, service costs	224,405,000	193,239,000
Selling, general and administrative	37,922,000	32,276,000
Income from operations	18,118,000	8,945,000
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	26,576,000	27,281,000
Income from operations	-26,576,000	-27,281,000
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Restructuring costs	($5,324,000)	($1,008,000)

Segments_Depreciation_and_Amor

Segments - Depreciation and Amortization Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$30,329	$29,088
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	23,876	22,970
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	5,208	4,891
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$1,245	$1,227

Earnings_Per_Share_Summary_of_

Earnings Per Share - Summary of Weighted-Average Outstanding Share-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Weighted average shares subject to anti-dilutive share-based awards	1,043	766

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event [Member], USD $)	1 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2015
Subsequent Event [Member]
Subsequent Event [Line Items]
Equity repurchase program additional authorized amount	$300
Equity repurchase program authorized amount	$360